Navigation Links
Eloxatin combination reduces bowel cancer recurrences

Bowel cancer is one of the most common cancers occurring in humans. A clinical study involving patients taking supplementation of Eloxatin drug with other chemotherapeutic cancer drug for treatment of bowel // cancer has found better prognosis and reduced recurrence in these patients. This study which is called as NICE study has proved a combination of Eloxatin with chemotherapeutic drugs more effective than control group which received only cancer chemotherapeutic drug such as 5-Fluorouracil and Folinic acid.

The study has found combination of Eloxatin with 5-Fluorouracil and Folinic acid more effective in treating early bowel cancer compared to control group. International trials show that adding Eloxatin to the standard chemotherapy combination helps reduce the risk of relapse after surgery by 25%.

Experts View:

Hilary Whitaker, chief executive of Beating Bowel Cancer said, "It's impossible to overstate the importance of this decision by NICE for the thousands of people diagnosed every year with early stage bowel cancer and we want all eligible patients to have access to the best chance of cure and although the final guidance may take some months to be confirmed, patients should start speaking now to their clinicians to ensure that they are offered the option of the most effective treatment for their particular type of bowel cancer."

Dr Harpreet Wasan, medical oncologist at Hammersmith Hospital in London said, "This is a landmark decision by NICE in the treatment of bowel cancer, which will be welcomed by clinicians and patients alike.”

Source: BBC News.
'"/>




Page: 1

Related medicine news :

1. The bad combination
2. Warding off symptoms of premenstrual syndrome by combination therapy
3. Cholesterol can be lowered using combination of Soy Proteins and Sterols
4. Nanocells cancer combination therapy acts as chemotherapy as well as anti-angiogenic drug
5. Calcitriol [Vitamin D] with combination of painkillers for cancer treatment
6. Chloroquine and Primaquine combination Malarial drug for resistant parasites.
7. Death from heart attack can be reduced by new drug combination
8. New tetanus-diphtheria combination vaccine launched by Serum Institute of India
9. More effective Antiretroviral HIV drug combination
10. Salmeterol - to be used in combination & only when required
11. New chemo combination to fight breast cancer better
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... ... 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ), ... official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the practice, ... says the decision to support the pageant in an official capacity is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern Illinois ... are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy ... Gateway Convention Center in Collinsville. , They expect to treat approximately ...
(Date:6/24/2016)... Austin, TX (PRWEB) , ... June 24, 2016 , ... ... laude graduate, joins Evans Dermatology in the South Lamar location as of July 13, ... Texas Southwestern Medical School. As a medical student, she regularly volunteered at the Agape ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: